|
1. BIOLOGIE
| |
|
New insights into a rare type of cancer open novel avenues of study [Karolinska Institutet]
| |
| | |
|
Undifferentiated uterine sarcoma is a very rare but extremely aggressive cancer type. It can be divided into four groups with different characteristics of clinical importance - a new study at Karolinska Institutet reveals. The results, published in the journal Clinical Cancer Research, also show that the survival rate of patients with a certain type of tumour is better than predicted.
| |
| | |
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
| |
|
|
4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...
| |
|
|
4.5 DÉP., DIAG. & PRONO. - COLORECTAL
| |
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
| |
|
|
5.12 IMMUNOTHÉRAPIES
| |
|
Could Immunotherapy Offer a Cure for Cancer? [NY Times]
| |
| | |
|
The new book by Charles Graeber, “The Breakthrough: Immunotherapy and the Race to Cure Cancer,” artfully traces the history of old and new developments that may have — finally — resulted in an actual cure for the most dreaded of all diseases.
| |
| | |
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
| |
|
Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact [Fierce Biotech]
| |
| | |
|
Sanofi has the option to opt in to the two clinical assets—BCMAxCD3 and MUC16xCD3 bispecific programs—when they achieve proof of concept or further funding is required. Regeneron will spend up to $70 million to develop the BCMAxCD3 drug in multiple myeloma and as much as $50 million on the MUC16xCD3 bispecific in mucin-16 expressing cancers.
| |
| | |
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
| |
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
| |
|
|
5.2 PHARMA
| |
|
AstraZeneca announces organisational changes [AstraZeneca]
| |
| | |
|
"I am delighted to welcome José to AstraZeneca. An outstanding scientific leader in Oncology, José’s research and clinical achievements have led to the development of several innovative medicines, and he is an international thought leader in cancer care and clinical research."
| |
| | |
|
|
|
AstraZeneca picks Baselga to lead oncology R&D in growth plan [Reuters]
| |
| | |
|
Baselga, who also worked as chief of hematology/oncology at the Massachusetts General Hospital Cancer Center and has been a professor at Harvard Medical School, said his position at AstraZeneca was newly created and brought discovery through to late-stage development chain into one unit.
| |
| | |
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
| |
|
|
|
|
|
Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics [STAT]
| |
|
| |
|
Even if Loxo never starts work on another drug, the deal already means two more for Lilly: a follow-up to Vitrakvi, for patients who become resistant to that drug, and a new molecule for patients who have become resistant to AbbVie’s Imbruvica or similar medicines used to treat some leukemias and lymphomas. That could be a substantial market.
| |
| | |
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
| |
|
Human medicines: highlights of 2018 [EMA]
| |
| | |
|
In 2018, EMA recommended 84 medicines for marketing authorisation. Of these, 42 had a new active substance which has never been authorised in the EU before. Many of these medicines represent a significant improvement in their therapeutic areas; they include medicines for children, for rare diseases and advanced therapies.
| |
| | |
|
|
|
6.1 OBSERVATION
| |
|
How important is medical care to life expectancy gains? [Healthcare Economist]
| |
| | |
|
There is a stronger case that personal medicine affected health in the second half of the 20th century than in the preceding 150 years. Big medicine brought big benefits, especially to the older population, at big cost. In contrast, much of the health advance prior to the mid-20th century was a result of public health improvements, perhaps sometimes supported by physicians but not resulting from clinical therapies for individual patients.
| |
| | |
|
|
6.10 POLITIQUES
| |
|
|
|
6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
| |
|
|
6.7 DMP, BIG DATA & APPLIS
| |
|
|
6.7.1 IA/BIOINFORMATIQUE
| |
|
|
6.9 CONTROVERSES
| |
|